DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with ...
The CONNECT trial found greater A1C reductions and more time in target glucose range among adults using continuous glucose monitoring.
A list of domestic and international medical and healthcare news for the past week, along with brief commentary. On October ...
DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...
DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...
Dexcom G7 15 Day continuous glucose monitoring (CGM) system will be available in Canada beginning in November for adults aged 18 and older living w ...
DexCom Inc. DXCM recently announced that its G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan.
I started monitoring my blood glucose levels by wearing a Libre while hospitalized after being diagnosed with Type 1 diabetes ...
DexCom, Inc. announced that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results